GefitinibEnfòmasyon
| Non pwodwi: | Gefitinib |
| Sinonim: | N-(3- chloro -4- fluoro-phenyl) -7- metoksi -6- (3- Morpholin -4- N-(3- chlor -4- fluorophenyl) -7- [methoxy -6- [(3- morpholin -4- yl) propoxyl] -quinazolin -4-} yl) Gefitinib ki gen rapò konpoze; Gefitinib n-(3- chloro -4- fluoro-phenyl) -7- methoxy -6- (3- Morpholin {{25} Iressa; n-(3- chloro -4- fluoro-phenyl) -7- methoxy -6- (3- Morpholin {{34} |
| CAS: | 184475-35-2 |
| MF: | C22H24CLFN4O3 |
| MW: | 446.9 |
| Einecs: | 643-034-7 |
Pwopriyete chimik gefitinib
| Pwen k ap fonn | 119-120 degre |
| Pwen bouyi | 586.8 ± 5 0. 0 degre (prevwa) |
| Densite | 1.322 ± 0. 06 g/cm3 (prevwa) |
| Depo tanperati. | Chanm tanperati |
| Solubility | Soluble nan DMSO (jiska 40 mg/mL) oswa etanòl (jiska 4 mg/mL). |
| Pka | 7. 00 ± 0. 10 (prevwa) |
|
Fòm |
Poud |
|
Koulè |
Blan yo bèlj |
Gefitinib l '
| Itilize | Gefitinib se yon trè espesifik anti-timè vize dwòg ki ka geri ou devlope pa AstraZeneca nan UK la. Li se premye molekilè dwòg la vize yo itilize pou tretman pou kansè nan poumon ki pa ti selil (Chimik). Li egzèse efè li yo pa oaza anpeche chemen an siyal nan epidèrmik kwasans faktè a reseptè tirozin kinaz (EGFR-TK). |
Baj popilè: Gefitinib cas pa gen okenn. 184475-35-2, Lachin, Konpayi fabrikasyon, Swèd, faktori, Custom, Wholesale
